Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Thoracic 1

Conditions

Anemia 2Renal Anemia 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Epoetin Alfa 43Darbepoetin alfa 33epoetin beta 10ferric carboxymaltose 6Cyclosporine 4Cisplatin 4ferrous sulfate 3Radiotherapy 3Lenalidomide 3peginesatide 2luspatercept 2hematide 2fludarabine 2ferric gluconate 2continuous erythropoietin receptor activator 2Therapeutics 2Filgrastim 2Erythropoietin 2Dexamethasone 2Cyclophosphamide 2Brachytherapy 2Antilymphocyte Serum 2ACE-011 2thymoglobulin 1ruxolitinib 1roxadustat 1reolysin 1pegfilgrastim 1obinutuzumab 1leridistim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Anemia × continuous erythropoietin receptor activator × Clear all
NCT00327535 2016-08-11

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Hoffmann-La Roche

Phase 2 Completed
153 enrolled
Classical hematology

Anemia

NCT00072059 2013-07-18

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡